OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books
Apr 6, 2018 • 18min
Vincristine
The Foundations in Oncology Pharmacy continues with vincristine. Its origin, unique toxicity profile, and clinical use is discussed. Periwinkle!
Mar 30, 2018 • 26min
HOPA Highlights and Catching Up with NEJOncology
Highlights from last week's HOPA annual conference are discussed, followed by (13:09) a lightning-style run through of #oncopharm updates over the last 2 weeks.
Mar 16, 2018 • 11min
HOPA Preview
Previewing HOPA18 and its highly anticipated sessions, networking opportunities, and virtual attendance.
Mar 9, 2018 • 23min
Landmark Testicular Cancer Study PVB (& BEP & EP)
PVB's (cisplatin, vinblastine, bleomycin) impressive cure rate for testicular cancer is 1977 is discussed. Then the evolution of the BEP & EP regimen is summarized.
Mar 1, 2018 • 18min
Cycling thru the CDK Inhibitors
Abemaciclib's up-front approval provides an opportunity to review all 3 currently FDA-approved CDK 4/6 inhibitors. Dosing, drug interaction, and indication differences are discussed.
Feb 23, 2018 • 17min
It's All Immunotherapy Nowadays
Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.
Feb 15, 2018 • 29min
Apalutamide
Apalutamide's FDA-approval is discussed, including discussion of its drug interaction potential and a review of the SPARTAN study. Updates (18:15) from ASCO GU and DOAC use in cancer (23:50) also discussed.
Feb 9, 2018 • 21min
Landmarks in Oncology Pharmacy: CMF
The Landmarks series continues with Bonadonna's classic adjuvant CMF regimen in breast cancer in a pre-tamoxifen & pre-ER/PR testing era. Discussion points include number needed to treat (NNT) to prevent recurrence and how chlorambucil was considered for the 'C' in CMF.
Feb 2, 2018 • 15min
Foundations in Oncology Pharmacy: Doxorubicin
Overview of doxorubicin from its Italian origins to its Red Devil alias. Uses and toxicities also discussed, of course.
Jan 26, 2018 • 15min
Updates in Oncology Pharmacy: Lu-177
New Drug Approval: Lutetium-177-dotatate is discussed as well as updates to indications for denosumab (m. myeloma), afatinib, & olaparib.
